IL1B and chronic kidney disease: The causal role of inflammation in CVD among CKD patients was highlighted in secondary analyses from the CANTOS trial, which showed that canakinumab, an IL-1β monoclonal antibody, reduced major adverse cardiovascular events in CKD patients with prior myocardial infarction and persistently elevated C-reactive protein levels [63,64].